Key Details
Price
$2.90Annual ROE
-156.66%Beta
0.55Events Calendar
Next earnings date:
May 09, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 07, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 18, 2024Analyst ratings
Recent major analysts updates
16 Aug '23 HC Wainwright & Co.
Neutral15 Aug '23 Laidlaw & Co.
Hold15 May '23 HC Wainwright & Co.
Buy04 May '22 Wells Fargo
Overweight09 Nov '21 Raymond James
Market Perform10 Aug '21 Raymond James
Market Perform07 May '21 Raymond James
Outperform12 Mar '21 Jefferies
Hold01 Mar '21 HC Wainwright & Co.
Neutral19 June '20 Jefferies
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Alaunos Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
TCRT
Zacks Investment Research16 August 2023
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
TCRT
GlobeNewsWire29 March 2023
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
FAQ
- What is the primary business of Alaunos Therapeutics?
- What is the ticker symbol for Alaunos Therapeutics?
- Does Alaunos Therapeutics pay dividends?
- What sector is Alaunos Therapeutics in?
- What industry is Alaunos Therapeutics in?
- What country is Alaunos Therapeutics based in?
- When did Alaunos Therapeutics go public?
- Is Alaunos Therapeutics in the S&P 500?
- Is Alaunos Therapeutics in the NASDAQ 100?
- Is Alaunos Therapeutics in the Dow Jones?
- When was Alaunos Therapeutics's last earnings report?
- When does Alaunos Therapeutics report earnings?
- Should I buy Alaunos Therapeutics stock now?
What is the primary business of Alaunos Therapeutics?
Alaunos Therapeutics, known for its TCRT technology, focuses on developing personalized cancer treatments. The company uses a unique approach to harness the body’s immune system to target and destroy cancer cells, aiming to improve outcomes for patients with various types of cancer.
What is the ticker symbol for Alaunos Therapeutics?
The ticker symbol for Alaunos Therapeutics is NASDAQ:TCRT
Does Alaunos Therapeutics pay dividends?
No, Alaunos Therapeutics does not pay dividends
What sector is Alaunos Therapeutics in?
Alaunos Therapeutics is in the Healthcare sector
What industry is Alaunos Therapeutics in?
Alaunos Therapeutics is in the Biotechnology industry
What country is Alaunos Therapeutics based in?
Alaunos Therapeutics is headquartered in United States
When did Alaunos Therapeutics go public?
Alaunos Therapeutics's initial public offering (IPO) was on 24 August 2005
Is Alaunos Therapeutics in the S&P 500?
No, Alaunos Therapeutics is not included in the S&P 500 index
Is Alaunos Therapeutics in the NASDAQ 100?
No, Alaunos Therapeutics is not included in the NASDAQ 100 index
Is Alaunos Therapeutics in the Dow Jones?
No, Alaunos Therapeutics is not included in the Dow Jones index
When was Alaunos Therapeutics's last earnings report?
Alaunos Therapeutics's most recent earnings report was on 14 November 2024
When does Alaunos Therapeutics report earnings?
The next expected earnings date for Alaunos Therapeutics is 9 May 2025
Should I buy Alaunos Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions